Defeating malaria together

Access interviews

  • Prof Jean Louis Ndiaye, Cheikh Anta Diop University of Dakar, Senegal

    Cheikh Anta Diop University of Dakar, Senegal, conducted a pilot study from 2011 to 2012 combining SMC with home management of malaria. Prof Jean Louis Ndiaye explains the challenges and the potential impact of SMC. (2013)

  • Dr Philippe Lukanu Ngwala, General Reference Hospital, DRC

    There are around 5.6 million cases of severe malaria every year, leading to an estimated 627,000 deaths, mostly of children under 5 years of age. Dr Philippe Lukanu Ngwala, General Reference Hospital, Kimpese district, DRC, explains the advantages of using artesunate to treat severe malaria. (2013)

  • Dr Madan Mohan Pradhan, Deputy Director Health Services, NVBDCP, Ministry of Health & Family Welfare, Odisha

    The National Institute of Malaria Research and the National Vector Borne Disease Control Programme, with technical and financial support from MMV, are implementing the Comprehensive Case Management Programme in four districts of Odisha. Dr Madan Mohan Pradhan speaks about the roll-out of this programme. (2013)

  • Prof Abdoulaye Djimde, University of Science, Techniques and Technologies of Bamako, Mali

    To help gather evidence to guide the optimal and widespread use of new ACTs, MMV works with partners to study how they fare in the real world. Prof. Abdoulaye Djimde talks about the WANECAM trial and what it has revealed so far. (2013)

  • Dr Keziah Malm, National Malaria Control Progamme, Ghana

    Artemisinin-based combination therapies (ACTs) are the current WHO-recommended standard of care for uncomplicated malaria. Dr Keziah Malm provides insight into the real-world advantages of multiple first-line ACTs, which were first instituted in Ghana in 2007. (2013)

  • Prof. Olugbenga A Mokuolu, Centre for International Education, University of Ilorin, Nigeria

    In 2011 the WHO revised its Standard Treatment Guidelines to recommend artesunate injection as the preferred treatment for severe malaria. Prof. Olugbenga A Mokuolu explains how the guideline change was made in Nigeria and what impact it has had. (2011)

  • Dr Jane Achan, Makerere University, Kampala, Uganda

    With the exception of Coartem® Dispersible, few antimalarial medicines have been specifically formulated for children. Dr Jane Achan explains the needs on the ground for doctors treating children suffering from malaria. (2011)

  • Dr Elizabeth Juma, National Malaria Control Programme, Kenya

    Pregnancy lowers a woman’s immune response to infections and so she is four-times more likely to get malaria and twice as likely to die from it than another adult. Dr Elizabeth Juma explains the Kenya's approach to protecting pregnant women from malaria. (2011)

  • Mr Winna Shango, Ministry of Health and Social Welfare, Tanzania

    SMS for Life uses widely available SMS technology to record antimalarial stock levels at the point-of-care. Mr Winna Shango tells us how this programme is motivating health-care workers in Tanzania. (2011)

  • Mrs Esnet Mwape, Pharmaceutical Regulatory Authority, Zambia

    ACTs are currently the best medicines available to treat uncomplicated malaria but unfortunately many patients lack access to them. Ms Esnet Mwape explains how the medicinal products coming into Zambia are now better regulated. (2011)

  • Nettie Dzabala, College of Medicine, Malawi

    The College of Medicine is an academic centre of excellence, responsive to the health needs of Malawi by training professionals, providing clinical services and medical research. MMV worked with the college to analyze the antimalarial medicines market in six districts. (2011)

  • Mr. Yu, President of Guilin Pharmaceutical, Mr. Long, Head of the Guilin office of the State Food and Drug Administration, Mr. Wu, Vice Mayor of Guilin City, responsible for Health and Education

    Guilin Pharmaceutical has been producing injectable artesunate for patients with severe malaria since 1987. But without WHO prequalification or stringent regulatory approval, it could not be purchased by international organizations or donor funds and was thus not reaching this vulnerable group. This interview discusses the MMV-Guilin partnership, leading to Guilin Pharmaceutical becoming the first WHO prequalified pharmaceutical company worldwide to produce artesunate for injection. (2010)

  • Dr Arjen Dondorp, Deputy Director and Head of Malaria Research,Mahidol–Oxford Tropical Medi-cine Research Unit, Bangkok, Thailand

    MMV is using its R&D know-how, working with Guilin Pharmaceutical to achieve WHO prequalification for injectale artesunate, treatment for severe malaria. Dr Arjen Dondorp, speaks about treating patients with of severe malaria. (2010)